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1. Introduction 
The interleukin 1 (ILl) family of proteins currently 
comprises ILl or, ILl/3 and the ILl receptor antagonist, 
IL1RA. The biological activities of ILl are shared by 
I L la  and ILl/3, with IL1RA acting as a true receptor 
antagonist [1]. Much interest has surrounded the many 
responses induced by ILl as its effects both in vitro and in 
vivo have led to it being implicated in a number of 
pathological conditions, most notably chronic inflamma- 
tory diseases uch as rheumatoid arthritis. Whether ILl has 
a role to play in normal physiology is still a matter of 
debate. Originally described as a comitogen for T lympho- 
cytes [2], it is now clear that ILl can activate awide range 
of cell types with roles in both immunity and inflamma- 
tion. The end result of ILl action on target cells is a 
change in gene expression and ILl may be thought of as 
an extracellular agent which allows cells to exhibit their 
activated phenotype. For example, fibroblasts when acti- 
vated produce a range of proteins, including tissue degrad- 
ing enzymes and cytokines, and will also increase the 
output of prostaglandins. ILl will enhance all of these 
activities through an alteration in the expression of discrete 
genes. The molecular basis for the changes in gene expres- 
sion is unclear, despite being an area of close scrutiny for 
the last ten years. Efforts have focused on attempts to 
implicate known second messengers and protein kinases in 
ILl signalling and to link such changes with transcription 
factor activation. Such attempts have often proved contro- 
versial with no clear consensus emerging [3,4]. More 
recently, novel pathways and protein kinases have been 
described. This review will attempt to distil the key fea- 
tures of ILl signal transduction published to date and 
speculate on the importance of observations made. 
2. IL l  receptors 
Two distinct plasma membrane receptors have been 
described for ILl. The first to be described was an 80 kDa 
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Fig. 1. Characteristics of the Type I ILl receptor. Amino acid sequence 
analysis and site-directed mutagenesis studies have revealed the main 
features of the Type I IL1R, as shown above. Deletion of the region from 
amino acids 477 to 527 abrogates ignal transduction [17]. Six amino 
acids (arginine 431, phenylalanine 513, tryptophan 514, lysine 515, 
arginine 518 and tyrosine 519) are conserved in human, mouse and 
chicken IL1RI and the Drosophila melanogaster protein Toll [17,18]. 
Mutation of these residues produces a receptor incapable of signalling. 
glycoprotein [5]. Early reports characterised this receptor 
by performing receptor cross-linking analysis and ligand 
binding studies on a variety of cell types. Features of the 
receptor included its high affinity for ILl (dissociation 
constants in the picomolar ange), the fact that both ILl a 
and ILl/3 bound to the same receptor and the relatively 
low number of receptors per cell (on average 1-200) [6]. 
Although the 80 kDa form was the main species een on 
cross-linking of T cell or fibroblast membranes with 
[125I]IL1, a 60 kDa species was seen on B cells [7]. These 
were eventually shown to be two distinct proteins and 
were named Type I and Type II ILl receptors (IL1RI and 
IL1RII, respectively) [8,9]. 
2.1 .~1~ 
IL1RI was cloned from mouse and human cells and was 
shown to occur on T cells, fibroblasts and endothelial cells 
[10-12]. When transfected into Chinese hamster ovary 
cells IL1RI conferred responsiveness to ILl in these cells 
[13]. Disappointingly, its structure gave no clues as to a 
possible signal transduction pathway. The key structural 
features of the receptor are shown in Fig. 1. IL1RI does 
not possess any intrinsic protein kinase activity. The murine 
form of the receptor has been shown to become phospho- 
rylated on threonine 537 in response to phorbol esters 
although this did not affect receptor function [14]. The 
human form has no sequence homology in this region and 
is not phosphorylated [14]. ILl does not increase phospho- 
rylation of murine ILIRI. Phosphorylation f ILIRI there- 
fore does not appear to be important for receptor sig- 
nalling. 
Nuclear translocation motifs have been found in both 
human and murine ILIRI [11]. These sequences occur near 
the C-terminus in the vicinity of amino acids 522-531 and 
428-432. There have been demonstrations of a transloca- 
tion of I L l / I L l  RI complexes to the nucleus suggesting 
that such translocation is important for ILl-induced gene 
expression [15,16]. Elegant receptor mutation studies car- 
ried out by Heguy et al. and Kuno et al. [17,18], however, 
have ruled out this possibility. They have demonstrated 
that mutating the nuclear translocation motif in the murine 
ILIRI prevents receptor trafficking without affecting 
changes in gene expression [18]. They have further shown 
that deletion of most of the cytoplasmic portion of IL1RI 
had no effect on ILl-induced PGE2 and GMCSF in fibrob- 
lasts or IL2 production in Jurkat T cells [17]. A crucial 50 
amino acid segment spanning residues 477 to 527 was 
identified, however, and shown to be highly homologous 
to the avian and human ILIRI [17]. 
Another sequence similarity has been described by Kuno 
et al. [18] in the murine form of ILIRI. Amino acids 
435-484 are homologous to gp130 of the IL6 receptor. 
Truncation mutants and point mutations within this seg- 
ment were found to abolish the ability of the receptor to 
induce IL8 expression. As IL6 is unable to induce IL8 it 
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was suggested that the gpl30 homologous region may 
contribute to the maintenence of the basic structure of the 
receptor ather than to the interaction with a putative 
second messenger molecule(s). 
2.2. ILIRI and Toll 
The only other protein so far identified that exhibits 
significant sequence similarity to ILIRI is Toll protein, a 
membrane protein in Drosophila melanogaster, which has 
been shown to play a key role in the generation of 
dorsoventral polarity in the early Drosophila embryo 
[19,20]. The similarity is ,only apparent in the cytoplasmic 
domain of both proteins, extending for 135 amino acids 
throughout most of the domain. The significance of the 
highest scoring matches is extremely high, with identical 
or conservatively substituted amino acids being found at 
45% of positions. This unexpected sequence similarity 
suggests that the signal transduction pathway triggered by 
IL1RI and Toll are likely to by shared. In particular, the 
events stimulated by ILl which lead to activation of the 
transcription factor NFKB are likely to be identical to 
those stimulated by Toll which lead to activation of dorsal, 
the Drosophila NFKB homologue. Genetic analysis has 
revealed that two other genes, tube and peUe, are ex- 
pressed uring the generation of dorsoventral polarity, and 
that these act sequentially in the pathway leading from Toll 
to dorsal [21,22]. Both tube and pelle have been cloned 
[21,22] and pelle codes for a serine/threonine protein 
kinase related to raf-1 [122]. Raf-1 has been shown to 
directly activate NFK B in Jurkat T cells [23,24]. Whether a
similar system is operating in the activation of NFK B by 
ILl has yet to be demonstrated (see below for further 
discussion on NFK B). Because of the similarities in the 
Toll/dorsal and IL1RI/NFKB pathway it is likely that the 
protein(s) which interact 'with the cytoplasmic domains of 
both Toll and IL1RI will be closely related. Possible points 
of contact have been suggested from the work of Heguy et 
al. [17] who have identified six key amino acids in IL1RI 
from chicken, human and mouse and in Toll [21] (Fig. 1). 
In human IL1RI these correspond to Arg431, Phe513, 
Trp514, Lys515, Arg518 and Tyr519. All of these have 
been shown to be critical for the activation of the IL2 
promoter in T cells by ILl, suggesting that these key 
amino acids for IL1RI function will be similarly crucial for 
Toll function. Interestingly, Kuno et al. [18] have found 
that the three basic residues in murine IL1RI which corre- 
spond to those described by Heguy et al. [17] in human 
IL1RI are not essential for the induction of IL8 by ILl. 
This suggests that different cytoplasmic elements are re- 
quired for IL2 and IL8 gene activation, indicating that the 
signals generated by ILl may depend on the particular 
final response under investigation. 
2.3. ILIRII 
IL1RII was first identified on cells or cell lines repre- 
sentative of B cells, monocytes, neutrophils, bone marrow 
cells and hepatoma cells [7,25-29]. Initially a second 
receptor type for ILl was suggested because of differences 
in size and/or antigenicity from the receptors found on T 
cells and fibroblasts. The receptor was subsequently shown 
to be a product of a different gene and was cloned from 
murine and human B cells [9]. Structurally, the extracellu- 
lar domain of IL1RII is 28% similar in amino acid se- 
quence to IL1RI, with three immunoglobulin-like domains. 
Most interestingly, the intracellular portion of IL1RII com- 
prises only 29 amino acids in contrast o the 215 amino 
acids of IL1RI. This initially suggested that both receptors 
would interact with different signal transduction pathways 
but it has since become clear that IL1RI, and not IL1RII, is 
the signalling receptor for ILl. This conclusion is based on 
the fact that blocking antibodies to IL1RI but not IL1RII 
inhibit ILl action even on cells shown to predominantly 
express IL1RII [30,31]. Secondly, in murine cells the 
human IL1RA will only inhibit binding to IL1RI and is 
inhibitory for ILl signals [30]. A role for ILIRII in ILl 
signalling involving dimerisation between IL1RI and II has 
also been ruled out [32]. The most likely function of 
IL1RII is as a regulator of ILl levels extracellularly as it 
has been shown to be shed from cells [33,34], and an 
interesting sequence similarity has been found with a 
protein from Vaccinia virus which is used to decrease host 
immune responses to the virus [35,36]. IL1RII may there- 
fore function as an extracellular ILl inhibitor, binding to 
ILl and preventing it from interacting with IL1RI [34]. 
3. G proteins and second messengers 
Early attempts to determine the number of ILl receptors 
per cell revealed that most cell types expressed < 500 [6]. 
Further investigations involving receptor occupancy stud- 
ies, transfection of receptor-negative cells with the IL1RI 
gene [11] and studies with radiolabelled human IL1RA on 
70Z/3 murine B cells [30] demonstrated that less than 10 
receptors per cell were sufficient o cause cellular activa- 
tion. These data suggest that a major amplification in 
signal must occur following ILl binding. Classical hor- 
monal signal amplification occurs through the coupling of 
receptors to guanine nucleotide binding proteins (G pro- 
teins) with the subsequent generation of second messen- 
gers such as cyclic AMP (cAMP), diacylglycerol and 
inositol trisphosphate and calcium. These systems have 
been investigated for ILl and have been the subject of 
much controversy with data being presented both for and 
against heir involvement in the ILl signalling pathway. 
3.1. Is a pertussis toxin-sensitive G protein important for 
ILl signalling? 
Several groups have published evidence for G protein 
involvement in ILl action. Much of the evidence rests 
upon the inhibitory effect of pertussis toxin on post-recep- 
tor events triggered by ILl [37-43]. The toxin has been 
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found to inhibit several such responses as listed in Table 1. 
Pertussis toxin inactivates G i and Go-class G proteins [44] 
and as a consequence Gi-like G proteins have been in- 
voked as transducers for the ILl signal. In conjunction 
with these studies ILl has been shown to increase the 
binding of a non-hydrolysable analogue of GTP, GTP~/S, 
to membranes prepared from EL4.NOB-1 thymoma cells 
[39]. Increased hydrolysis of GTP has also been reported in 
ILl-stimulated membranes from EIA.NOB-1 and 70Z/3 
pre-B cells [37,39]. There have been reports of ILl inhibit- 
ing adenylate cyclase activity in pituitary cells [45] and of 
another non-hydrolysable analogue of GTP, p[NH]ppG, 
causing a higher affinity state for ILl binding in EL4 
membranes [46]. Taken together these data suggest hat a 
pertussis toxin-sensitive G protein (most probably G i) has 
a role to play in ILl signalling. Recent evidence, however, 
questions this conclusion. Firstly, pertussis toxin does not 
inhibit all responses to ILl. The activation of NFKB, 
phosphorylation f the EGF receptor, induction of collage- 
nase, IL6 and IL1RII have been shown to be insensitive 
[43,47]. Furthermore, for responses which are sensitive to 
pertussis toxin (for example, induction of IL2 and PGE2 
production) the B oligomer of the toxin, which is devoid of 
ADP-ribosylating activity and would therefore not inter- 
fere with G protein function, has been shown to be as 
inhibitory as the holotoxin [47]. The basis for the in- 
hibitory effect of pertussis toxin therefore awaits elucida- 
tion. 
In spite of this, the reported changes in GTP binding 
and hydrolysis and the effect of p[NH]ppG on ILl binding 
would suggest hat the ILl receptor can couple to a G 
protein. The mechanism of this coupling is likely to be 
different to that exhibited by conventional G-protein linked 
receptors as the receptor does not possess the classical 7 
transmembrane domain structure of most G protein-cou- 
pled receptors [48]. This is further suggested from the 
observation that p[NH]ppG actually increases ILl binding 
rather than causing the characteristic decrease (termed 
negative heterotropic nteraction) which is observed with 
classical trimeric G proteins [46]. Evidence has been pro- 
vided for other agents whose receptors do not possess the 
seven transmembrane domain motif coupling to G pro- 
teins. These include IL2 [49], EGF [50], TGFfl [51], 
insulin [52], IGFII [53] and TNF [54] whose receptor has 
been co-purified with a G protein of unknown identity 
[55]. As TNF and ILl share many biological responses and 
most probably induce similar post-receptor signals it is 
possible that ILIRI complexes to and increases the activity 
of a similar G protein. Such coupling may involve 
phosphorylation as the activity of the a subunit of G i is 
modified by phosphorylation [56]. The nature of such a G 
protein and its importance for ILl signalling, however, 
awaits determination. As may be the case with other 
reported signals for ILl, changes in G protein activity may 
be a consequence of overall cellular activation, rather than 
having a determining role in ILl signal transduction. 
3.2. cAMP and IL l  
In 1988, Shirakawa et al. [57] reported that ILl could 
increase cAMP and activate adenylyl cyclase in a variety 
of cell lines and that forskolin, which directly stimulates 
adenylyl cyclase could mimic the effects of ILl in lympho- 
cytes and thymocytes. The increase in cAMP was subse- 
quently shown to be sensitive to pertussis toxin [37]. 
Earlier workers had attempted to implicate cAMP in ILl 
signalling in chondrocytes and failed [58]. Furthermore, 
other workers showed that increasing cAMP in lympho- 
cytes rather than causing activation, inhibited proliferation 
and IL2 production [59,60]. Subsequent s udies by several 
other laboratories failed to find changes in cAMP in 
response to ILl in several cell types, of both lymphoid and 
non-lymphoid origin [46,61-64]. The reason for these 
discrepancies i unclear. Most of the studies have been 
carried out in transformed cells and differences in cell 
types or strains may be partly responsible. There is also the 
possibility that increases in cAMP may be indirect and 
may be secondary to prostaglandin production [65]. 
Whether ILl can activate protein kinase A as a conse- 
quence of cAMP accumulation has also not been demon- 
strated directly and the phosphorylation changes charac- 
terised to date in response to ILl have not been shown to 
be due to protein kinase A (see below). Finally, Munoz 
and co-workers [66] have dissociated changes in cAMP 
Table 1 
Inhibition of ILl-induced responses bypertussis toxin 
Cell type Response Ref. 
70Z/3 pre-B cells r Ig L chain expression [37] 
YT natural killer cells IL2 receptor a chain expression [37] 
Rheumatoid synovial cells PGE2 production [37] 
EL4.NOB-1 thymoma cells Diacylglycerol accumulation [38] 
EL4.NOB-1 thymoma cells IL2 production [39] 
MIA PaCa pancreatic cells M-CSF production [40] 
Mesangial cells Phosphatidate phosphohydrolase activation [41] 
Hippocampal neurons Inhibition of calcium channel currents [42] 
Rinm5F pancreatic /3 cells Induction of ILl RI [43] 
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from several ILl responses in Th2 cells. The conclusion 
must therefore be that cAMP is unlikely to be a second 
messenger for ILl. 
3.3. Phospholipid-derived second messengers 
ILl has been shown to cause the breakdown of 
phospholipids in a variety of cell types. An increase in 
arachidonic acid release from membrane phospholipids via 
phospholipase A2 activalion has been demonstrated in
synovial fibroblasts [67], chondrocytes [68] and mesangial 
cells [69]. Recent work carried out by Gronich et al. [70] 
has demonstrated that ILl activates the cytosolic form of 
phospholipase A 2 (cPLA 2) by phosphorylating the en- 
zyme. As cPLA 2 in other systems has been shown to be 
phosphorylated by mitogen activated protein kinase (MAP 
kinase) [71], the authors ,;uggest hat the effect of ILl is 
similarly due to activation of MAP kinase, as ILl has been 
found to activate MAP kinase [72,73]. 
Increases in diacylglycerol have been reported in differ- 
ent cell types although the phospholipid source varies: in T 
cells this has been shown to be phosphatidylcholine [74], 
in macrophages, phosphatidylinositol [75], and in mesan- 
gial cells phosphatidylserine [76]. The breakdown of phos- 
phatidylinositol in response to ILl does not occur in most 
cell types, however, and there is a consensus that ILl does 
not cause an increase in intracellular calcium [77,78], 
which is consistent with the lack of evidence for inositol 
trisphosphate generation. However, a recent report has 
shown activation of nuclear phospholipase C/3 with subse- 
quent hydrolysis of phosphatidylinositol 4,5-bisphosphate 
in SaoS osteosarcoma cells [79]. 
There have also been reports of phosphatidic acid gen- 
eration in EL4 thymoma cells with subsequent generation 
of diacylglycerol via the activation of phosphatidate phos- 
phohydrolase [41]. ILl has also been demonstrated to
activate phosphatidylinos:itol-3-kinase activity in fibrob- 
lasts [80]. The activation of this enzyme is a common 
event for many different .growth factors [81]. The signifi- 
cance of its activation by ]iLl may relate to the observation 
that the product of phospllatidylinositol-3-kinase, phospha- 
tidylinositol-3,4,5-trisphosphate has b en shown to activate 
protein kinase C~ [82]. If ILl is able to activate protein 
kinase C~ by such a mechanism, this may explain the 
differences in phosphorylation patterns observed in cells 
stimulated with ILl and phorbol myristate acetate (PMA) 
(see below), as protein l~(nase C~ is insensitive to PMA 
[83]. 
The importance of these observations for subsequent 
events is unclear. The generation of arachidonic acid is the 
first step in prostaglandin production, although the induc- 
tion of cyclooxygenase by ILl would appear to have a 
more important role in the triggering of this response 
[84,85]. Recently, evidence has been presented for arachi- 
donic acid released in response to ILl, activating the 
transcription factor AP1 (,~ee below) and from there induc- 
iLl / IL1RI ? ~" ISPHINGOMYELINASEI 
~ Phosphorylcholine 
Diacytglycerol Phosphatidylcholine 
Fig. 2. The sphingomyelinase (SM) cycle. Sphingomyelin hydrolysis in 
response to ILl has been reported [88,89]. This scheme illustrates a 
putative cycle which may operate in stimulated cells. The product of 
sphingomyelinase, c ramide, may act as a second messenger as indicated 
and can be re-esterified to sphingomyelin through a reaction with phos- 
phatidylcholine [90]. 
ing granulocyte-macrophage colony stimulating factor in a 
bone marrow stromal cell line [86]. The generation of 
diacylglycerol would suggest that protein kinase C activa- 
tion may be important although, as discussed below, there 
is a consensus that this kinase is not activated in response 
to ILl in most cell types. Furthermore, in a cell type where 
diacylglycerol generation has been shown to occur (Detroit 
532 fibroblasts) no protein kinase C activation has been 
observed [87]. 
Most recently the sphingomyelin breakdown product 
ceramide has been shown to be generated in response to 
ILl in both EL4 thymoma cells [88] and fibroblasts [89]. 
The 'sphingomyelin cycle' represents a novel signal trans- 
duction pathway and is shown in Fig. 2 (reviewed recently 
in [90]). Ceramide has been shown to activate a protein 
kinase and a member of the protein phosphatase 2A family 
[90] indicating that it may act as a second messenger. 
Sphingomyelin turnover was originally shown to be stimu- 
lated by TNF, interferon-'y and vitamin D-3 in the myeloid 
cell line HL60 [91]. A series of experiments have sug- 
gested that sphingomyelin hydrolysis may also be a key 
step in ILl signalling. Evidence includes the ability of 
sphingomyelinase to mimic ILl-induced IL2 production in 
EL4 [88], the potentiating effect of sphingosine, ceramide 
and sphingomyelinase on ILl-induced prostaglandin pro- 
duction in fibroblasts [89,92], the activation of a 
ceramide-regulated protein kinase by ILl [88] and finally 
sphingomyelin hydrolysis and ceramide generation i  re- 
ponse to ILl [88,89]. A similar pathway has been invoked 
in studies with TNF, again suggesting a common signal 
[91]. Finally, ceramide and sphingomyelinase have been 
shown to activate the transcription factor NFKB in HL60 
[93]. As mentioned previously, activation of NFK B is an 
early signal triggered in response to ILl. The effect of 
ceramide on NFKB, however, may be cell-type or cell- 
strain specific as other reports have failed to show a link 
between sphingomyelinase activation by TNF and NFKB 
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in Jurkat and HL60 [94,95]. Whether the sphingomyelin 
pathway represents a general signal transduction pathway 
in all cell types and for all ILl responses therefore awaits 
further investigation. The fact that sphingomyelin break- 
down products on their own failed to cause prostaglandin 
production in fibroblasts [89] would suggest that ILl may 
provide other signals necessary for this effect. Further 
complexity is indicated from the suggested role of sphin- 
golipid breakdown products in tumour suppression and 
inhibition of proliferation [96,97]. Reports on the effects of 
ILl on cell proliferation have been conflicting, with ILl at 
best being a weak mitogen which probably acts indirectly 
[98]. This would suggest that the sphingomyelin cycle may 
have other roles to play in cellular activation, or alterna- 
tively may represent another general change which occurs 
in the activation of cells by ILl. A role for ceramide in ILl 
signalling is further questioned, however, from studies 
demonstrating that ceramide activates protein phosphatase 
2A. Other reports have indicated that ILl inhibits this 
enzyme as described in more detail in section 4.3 below. 
Further experiments are therefore necessary to clarify how 
important this pathway is likely to be in ILl signalling. 
4. Protein phosphorylation changes and IL l  
ILl causes a wave of protein phosphorylation within 
minutes of binding to fibroblasts. Studies involving high 
resolution two-dimensional gel electrophoresis have identi- 
fied at least 116 polypeptides whose phosphorylation state 
changes in response to both ILl and TNF [73]. The 
majority of these changes are an increase in phosphoryla- 
tion, although some represent a decrease. Most of the 
changes were shown to occur on serine or threonine 
residues with a small number occurring on tyrosine 
residues. A range of other agents were tested in order to 
determine how specific the changes were for ILl. PMA, 
epidermal growth factor (EGF), cAMP agonists, bradykinin 
and intefferons failed to mimic ILl, suggesting that neither 
growth factors nor protein kinases A or C were capable of 
triggering similar changes to ILl and thereby arguing 
against he involvement of these protein kinases in ILl 
action here. Only TNF and the protein phosphatase in- 
hibitor okadaic acid caused identical changes to ILl. The 
major phosphorylation change observed was of the small 
heat shock protein hsp27 [99]. Changes in phosphorylation 
of stathmin, eIF-4E, myosin light chain, nucleolin, EGF 
receptor, c-abl, retinoblastoma and p53 were also identi- 
fied. Earlier studies had demonstrated that ILl increased 
the phosphorylation f proteins in several cell types, in- 
cluding a 65 kDa protein in B cells [100] subsequently 
identified as 1-plastin [101]; in fibroblasts hsp27 [102,103], 
the EGF receptor [104,105] and the cytoskeletal protein 
talin [106] and in At-20 pituitary cells, stathmin [107,108]. 
The identity of the other substrates in fibroblasts is still 
ill-defined and the protein kinases which become activated 
in response to ILl have been under intense investigation. 
4.1. Protein kinase C 
Early work attempted to implicate known protein ki- 
nases in ILl signalling. Initially this focused on protein 
kinase C, as PMA, which directly activates protein kinase 
C, mimics many of the actions of ILl [72,109-111]. 
Reports have appeared showing activation of protein ki- 
nase C in T cells [112], mesangial cells [76], mouse 
fibroblast NIH 3T3 cells [113] and EL4 6.1 thymoma cells 
[114]. However, evidence has been presented questioning 
the importance of protein kinase C in ILl action. The 
phosphorylation pattern induced in fibroblasts by PMA 
differs markedly from that seen with ILl [73]. Most studies 
have shown that inhibitors of protein kinase C such as 
staurosporine fail to block a wide range of ILl responses 
in different cell types [109,115-121]. Interestingly, protein 
kinase C inhibitors uch as staurosporine and/or H7 have 
been shown to potentiate in response to ILl, IL2 and IL4 
production in EIA cells [118], PGE2 production in fibrob- 
lasts [117], proliferation in Th2 lymphocytes [66] and the 
induction of IL6 in monocytes [121]. Furthermore, stau- 
rosporine has also been found to potentiate TNF action 
[122]. This would suggest that protein kinase C may have a 
negative ffect on ILl and TNF signal transduction. Alter- 
natively, staurosporine may trigger responses of its own 
which lead to the observed potentiation. This is further 
suggested from studies howing a dramatic upregulation of
TNF receptors by staurosporine in myeloid and epithelial 
cells [122]. Staurosporine may therefore also upregulate 
ILl receptors and thereby increase the effect of ILl on 
cells. 
Further evidence against protein kinase C involvement 
has come from studies into the EGF receptor 
[72,104,105,123]. Similar to PMA, ILl decreases the affin- 
ity of this receptor for EGF, a process termed transmodula- 
tion [104]. The insensitivity of the ILl response to stau- 
rosporine, coupled with differences in phosphopeptide 
maps of the receptor generated by PMA and ILl indicated 
that protein kinase C was not involved in this response to 
ILl [105]. Subsequent work has gone on to demonstrate 
that ILl causes phosphorylation f the EGF receptor on 
threonine 669, whereas PMA causes phosphorylation  
threonine 654 [72]. 
Taken together, these data strongly argue against pro- 
tein kinase C involvement in ILl action. However, as most 
of the evidence is based on comparing ILl with PMA or 
the use of protein kinase C inhibitors, it is possible that an 
isoform which is insensitive to PMA and the inhibitors 
may be activated, for example protein kinase C~ [83], as 
described above. This has yet to be tested, however. 
4.2. MAP kinases 
The protein kinase responsible for the phosphorylation 
of the EGF receptor by ILl has been purified from KB 
epidermoid carcinoma cells and evidence has been pre- 
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sented for this enzyme being a member of the MAP kinase 
family [72]. Other workers have shown that ILl can acti- 
vate p42/p44 MAP-kinase and MAP kinase kinase in 
fibroblasts [73,124,125]. 111 common with several growth 
factors and TNF [73,126], ILl can therefore activate the 
MAP kinase pathway. Whether the kinases activated are 
identical to those triggered by other agents has yet to be 
demonstrated. Activation of the MAP kinase pathway by 
ILl may again be a consequence of overall cellular activa- 
tion, perhaps by cross-talk from other pathways, and the 
relevence of the changes induced for the specific signal 
generated by ILl is yet to be established. It is possible that 
activation of the MAP kinase pathway may be a common 
early event for many cel]tular activators with specificity 
being achieved downstream, as suggested recently by 
Brunner et al. in Drosophila [127] and in studies compar- 
ing EGF and NGF signal transduction i  PC12 cells [128]. 
Both studies indicated thai: although phenotypic responses 
to different stimuli varied according to the stimulus, MAP 
kinase activation was common to all stimuli studied. Sig- 
nalling pathways must either therefore diverge after MAP 
kinase, or alternatively involve additional early signals, 
perhaps other protein kinases, specific for each stimulus. 
Phosphorylation f hsp27 in response to ILl in KB cells 
has been shown to occur downstream of MAP kinase 
[129]. The phosphorylation sites have been identified as 
Ser78 and Ser82. These have also been shown to be 
phosphorylated by the MAP kinase substrate MAP kinase 
activated protein kinase 2 (MAPKAP kinase 2) [130] 
which may therefore be the ILl-activated MAP kinase 
substrate which phosphorylates hsp27. Putative protein 
kinase cascades culminating in hsp27 phosphorylation are 
shown in Fig. 3. Other evidence indicates that the hsp27 
kinase cascade activated by ILl may be novel (see below). 
4.3. Protein phosphatases 
The phosphorylation changes induced by ILl in fibrob- 
lasts are similarly induced by the phosphatase inhibitor 
okadaic acid [99]. This has led to the suggestion that ILl 
inhibits the action of a phosphatase, possibly protein phos- 
phatase-2A. The substrate for this phosphatase could be a 
kinase suppressor which is active in a de-phosphorylated 
form. Direct evidence has been provided for ILl and TNF 
inactivating a phosphatase, possibly protein phosphase 2A, 
one of whose substrates i hsp 27 [132,133]. This scenario 
may therefore have a role to play in increased phospho- 
rylation of hsp27, as described in Fig. 3. In addition, 
Growth factors ---~ Receptor 
,L 
ILl/ILl R1 ~ 
? ? 
~ [ MAP kinase kinase 
9 
I MAP kinase I 
[ MAPKAP kinase 2 (p50 hsp27 kJnase ?)1 
Phorbol esters 
I Protein kinase C I 
hsp27 phospho-hsp27 
Fig. 3. Protein kinase cascades leading to phosphorylation f hsp27. As described in the text, signals leading to the phosphorylation f hsp27 may converge 
on the enzyme MAPKAP kinase 2. The sequence of events leading from growth factor eceptors and protein kinase C to MAP kinase are well documented 
[131]. ILl has been shown to trigger the MAP kinase cascade in some cell types [72,99,124,125,129]. Evidence has also been presented for the activation 
of a novel protein kinase cascade which may culminate in a protein kinase related to or identical to MAPKAP kinase 2 [134]. The pathways indicated are 
all sensitive to protein phosphatase 2A which will dephosphorylate nd thereby inactivate MAP kinase kinase, MAP kinase, MAPKAP kinase 2, p35, p40 
and hsp27 itself [132-134]. ILl may therefore inhibit this enzyme which is susceptible to inactivation by phosphorylation tyrosine [132,133]. 
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evidence has been presented for both protein phosphatase 
2A and phosphotyrosine phosphatase 1B inactivating ILl- 
activated protein kinases [123,134]. This suggests that 
protein phosphatases are likely to be critical in the regula- 
tion of ILl action. ILl signalling may therefore involve a 
co-ordinate activation of kinases and inactivation of phos- 
phatases. 
4.4. Tyrosine kinases 
As mentioned previously, ILl has been shown to in- 
crease tyrosine phosphorylation i fibroblasts [99]. In- 
creases in tyrosine phosphorylation have also been re- 
ported in K562 cells [135], A375-C6 human melanoma 
cells [136], Th2 cells [137] and EL4 thymoma cells [138]. 
A consistent change occurs in proteins of 42-44 kDa 
[72,99,136,137], the molecular mass range for MAP ki- 
nases, and it has been suggested that these proteins are 
members of the MAP kinase family. Direct evidence has 
been provided for increased tyrosine phosphorylation f
p42 and p44 MAP kinases in response to ILl in KB cells 
[72]. This is likely to be due to MAP kinase kinase activity 
since, as mentioned previously, ILl activates this enzyme 
[125] and MAP kinase kinase activates MAP kinases by 
phosphorylating tyrosine and threonine residues [139,140]. 
The tyrosine kinases responsible for the increased tyrosine 
phosphorylation f the other proteins reported in A376-C6 
and Th2 cells [136,137] have yet to be identified. 
Studies with tyrosine kinase inhibitors have suggested 
that tyrosine kinase activation may be important for ILl- 
induced changes in gene expression. Induction of gro 
genes in melanoma cells, IL5 in T cells and PGE2 produc- 
tion in mesangial cells are inhibited by the tyrosine kinase 
inhibitor genistein [136,137,141]. Activation of the tran- 
scription factor NFrB can also be blocked by genistein 
and another tyrosine kinase inhibitor herbimycin A 
[136,138,142] (see below) which has also been shown to 
inhibit IL2 production in EL4 cells [142]. The precise 
target of these inhibitors has yet to be determined. 
4.5. Novel protein kinases 
The possibility that ILl is activating novel protein 
kinase(s) which initiate a specific signalling cascade has 
also been explored. These studies have focused on three 
substrates: a peptide derived from the EGF receptor, hsp27 
and fl-casein [102-105,123,124,134,143,144]. 
p54 MAP kinase 
As mentioned previously, a report has appeared charac- 
terising the protein kinase responsible for phosphorylation 
of a peptide derived from the EGF receptor in KB cells 
and suggesting that the enzyme responsible is a member of 
the MAP kinase family [72]. Recently, more extensive 
analysis has been carried out which has suggested that the 
enzyme is unlikely to be p42/p44 MAP kinase, based on 
substrate specificity (myelin basic protein and micro- 
tubule-associated protein-2 are weak substrates), lack of 
reactivity with antisera to p42/p44 MAP kinases and 
finally failure to reactivate the dephosphorylated form of 
the enzyme with MAP kinase kinase [123]. Most recently a
study carried out in rabbit has indicated that this kinase is 
likely to be p54 MAP kinase a [145], a member of 
JNK1/SAP family of kinases which phosphorylate c-jun 
[146]. This study involved treating rabbits with ILl and 
then purifying the kinase from liver. The isolated kinase is 
highly likely to be the rabbit form of the enzyme described 
in KB cells [123]. The p54 family appear to have their own 
upstream regulators which have yet to be determined [146]. 
Finally, TNF has recently been shown to activate JNK1 in 
NIH3T3 fibroblasts [146], further emphasising a role for 
this kinase in ILl and TNF signalling. 
hsp27 kinase cascade: HOG1 homologue /MAPKAP ki- 
nase 2 
hsp27 phosphorylation can be induced by a range of 
stimuli, including TNF, platelet derived growth factor, 
bradykinin, acid fibroblast growth factor, ATP and PMA 
[116]. It is therefore possible that hsp27 may be a substrate 
for several serine kinases, and recent evidence has sug- 
gested that the hsp27 kinase cascade activated by ILl may 
differ from that activated by PMA [124,134]. The hsp27 
kinase can use GTP or ATP, is insensitive to a wide range 
of protein kinase inhibitors and is highly specific for hsp27 
[124]. These data suggest hat the enzyme may be novel. 
Indeed most recently, evidence has been presented for a 
novel protein kinase cascade activated in response to ILl 
in KB cells which culminates in phosphorylation f hsp27 
[134] (described in Fig. 3). Three components were iso- 
lated in the cascade, an upstream activator of molecular 
ma~ss 35 kDa and two downstream components, of molecu- 
lar mass 40 kDa and 50 kDa, respectively. In vitro recon- 
stitution experiments have demonstrated that a protein 
kinase cascade is likely to be operating comprising p35 
p40 ~ p50 ~ hsp27, as shown in Fig. 3. Similar to the 
EGF peptide kinase described above [123], all three com- 
ponents are sensitive to inactivation by protein phos- 
phatase 2A. Biochemical evidence indicates that the en- 
zymes participating in the cascade are novel. Very recent 
evidence suggests that p40 is the human homologue of a 
recently reported murine protein kinase, p38, that becomes 
activated in response to endotoxin and hyperosmolarity 
[147]. The routine protein is related to mammaliam p42 
and p54 MAP kinases and to the Saccharomyces cere- 
visiae HOG1 gene product, which is also activated in 
response to changes in osmolarity, p50 hsp27 kinase re- 
sembles MAPKAP kinase 2 as previously described by 
Bird et al. [129] and may represent the human homologue 
of MAPKAP kinase 2, which was first described in rabbit 
[148]. Based on data presented by Bird et al. [129], and as 
suggested by Freshney et al. [134], MAPKAP kinase 2 
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may therefore be a point at which the MAP kinase and 
hsp27 cascades converge. However, recent evidence pre- 
sented by Rouse et al. [14!9] has suggested that MAPKAP 
kinase 2 is not a substrate for p42/p44 MAP kinase, 
indicating that both pathways are unlikely to converge. 
This work described a novel protein kinase cascade trig- 
gered by stress and heat shock which culminated in hsp27 
phosphorylation. This cascade appears to be identical to 
that triggered by ILl. Whether both this cascade or the 
'classical' p42/p44 MAP kinase cascade are triggered in 
response to ILl may be cell-type specific. In KB cells, ILl 
only weakly activates MAP kinase [123] whereas in MRC-5 
fibroblasts, there is a stronger activation [124]. Further 
complexity is suggested from the observation that PMA, 
which strongly activates MAP kinase in KB, does not 
activate the ILl-sensitive hsp27 kinase [124], distinguish- 
ing the enzyme from the MAPKAP kinase 2 which lies on 
the MAP kinase pathway. The precise relationship between 
the p40/p38/HOG1 pat]hway and the p42/p44 MAP 
kinase pathway therefore remains ambiguous. 
The significance of hsp27 phosphorylation for ILl ac- 
tion is unclear, as the physiological role(s) of hsp27, and 
hence phosphorylation f ]hsp27, is uncertain. It is present 
in almost all mammalian cells and is induced in response 
to heat shock and other :stresses. Like other heat shock 
proteins it is reported to have chaperonin-like properties 
[150], and its overexpression has been shown to increase 
thermotolerance and to inhibit cell proliferation [151,152]. 
hsp27 has also been shown to participate in actin polymeri- 
sation [153]. Phosphorylation f hsp27 may be essential for 
cytoskeletal changes in response to growth factor action, as 
recent work in fibroblasts has shown that the expression of 
a dominant negative mutant of hsp27 which could not be 
phosphorylated prevented growth factor-induced polymeri- 
sation of submembrane actin filaments and F-actin accu- 
mulation [154]. Whether ILl causes similar cytoskeletal 
changes through the phosphorylation f hsp27 has yet to 
be determined. 
r-Casein kinase 
The third novel kinase to be described has been termed 
r-casein kinase [124,14,4] because of its ability to 
phosphorylate /3-casein. It has been described in MRC-5 
gingival fibroblasts, chondrocytes and endothelial cells 
[124,144]. The enzyme is not activated by PMA and a 
wide range of other agent% including serum, basic fibrob- 
last growth factor and transforming rowth factor /31 
[124,144]. This is unlike hsp27 kinase which is activatable 
by a wide range of agents, as described above. The 
biochemical characteristics of the enzyme indicate that it 
has not been described before. It may be a multimeric 
enzyme with a 90 kDa :form being the smallest active 
component [144]. Interestingly, unlike the other protein 
kinases described above /3:-casein kinase is not inactivated 
by protein phosphatases. The fact that the enzyme is only 
activated by ILl and TNF makes it particularly interesting 
and suggests that it may be a key component in the 
specific signal triggered by these cytokines. Much work 
has yet to be done, however, and in particular its 
substrate(s) in cells have yet to be determined. 
In summary, the novel kinases described above are 
likely to be part of phosphorylation cascades triggered by 
ILl. Apart from /3-casein kinase whose amino acid se- 
quence has yet to be determined, they are all related to 
p42/p44  MAP kinase. Cascades involving 
p38/p40/HOG1 (which leads to hsp27 phosphorylation), 
p42/p44 MAP kinase and p54 MAP kinase/JNK1 are 
therefore likely to be triggered in cells treated with ILl. 
The extent to which each cascade is activated may be 
cell-specific and so far only p54 kinase has been demon- 
strated to be activated in vivo [124]. All three cascades 
also become activated in response to endotoxins and a 
range of physiological stresses. The early protein kinases 
in the cascades and a kinase associated with the liganded 
ILl receptor emain to be determined. Similarly, whether 
they are involved in the gene expression changes induced 
by ILl, possibly through phosphorylation f transcription 
factors, has yet to be discovered. 
5. ILl and transcription factors 
Transcription factors provide the link between post-re- 
ceptor signalling events and changes in gene expression. 
Phosphorylation plays a key role in regulating their activ- 
ity and there are many examples of phosphorylation con- 
trolling their nuclear translocation, DNA binding and 
transactivation [155]. ILl has been shown to activate 
and/or induce several transcription factors, including jun 
[156-158], los [159,160], NFrB [110,161], Myc [66], Egr- 
1, NAK-1, IRG-9 [162], Myb [66], c/EBP [163] and 
NFIL6 [164]. Most studies have focused on the fos-jun 
dimer AP1 and NFKB as a number of ILl-responsive 
genes have enhancers which contain AP1 and NFr B bind- 
ing sites. Some of these are shown in Table 2. 
5.1. AP1 
The predominant form of AP1 comprises a dimer of 
two proteins, fos and jun [181]. ILl has been shown to 
induce expression of los and jun in several cell types 
including the pituitary cell line AtT-20 [182] and HepG2 
cells [160], and jun in LBRM T cells [158]. The latter 
study indicated that induction of jun by ILl may be the 
basis of its co-stimulatory effect on T cells, whereby 
antigenic stimulation and ILl are both needed to trigger 
IL2 production. The antigenic signal (provided by phyto- 
hemaglutinin) was found to induce fos, thus to generate 
AP1, ILl induces jun and phytohemaglutinin induces los. 
AP1 activation by ILl has been shown to be critical for the 
induction of fl-endorphin in AtT-20 pituitary cells [182]. 
The mechanism by which ILl increases transcription via 
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AP1 may involve ILl-activated MAP kinase and 
p54/JNK1, as phosphorylation of jun by both of these 
kinases has been demonstrated and in the case of MAP 
kinase has been shown to be required for transcriptional 
activation by AP1 [183]. As mentioned previously, the 
generation of arachidonic acid in response to ILl may also 
be important for the activation of AP1 [86]. 
5.2. NFKB 
The predominant form of NFK B exists in resting cells 
in the cytosol as a dimer, p50 and RelA (formerly called 
p65), complexed to an inhibitory protein I KB [184]. As 
shown in Fig. 4, to activate NFK B, I x B must dissociate, 
allowing translocation of the NFK B dimer to the nucleus. 
ILl has been shown to activate NFKB in numerous cell 
types [30,110,161,185,186]. Direct dissociation of I KB 
and translocation has been demonstrated [186]. NFKB can 
be activated by a range of other agents, including viruses, 
double-stranded DNA, lipopolysaccharide, UV irradiation, 
oxidative stress and TNF [184]. All of these agents may 
use a common signalling pathway. Several models have 
been proposed to describe how NFKB is activated. These 
are summarised in Fig. 4. 
I r B can be dissociated chemically from NFK B in vitro 
with detergents such as deoxycholate [187]. In vitro phos- 
phorylation of I K B by protein kinase C, protein kinase A 
and casein kinase II also lead to dissociation [188], al- 
though whether these kinases also cause phosphorylation 
in vivo has yet to be directly demonstrated. Whether ILl 
can cause the phosphorylation f I r B is somewhat contro- 
versial, with evidence being presented both for and against 
this occurring [185,189]. Proteolysis of I K B has also been 
suggested as a key event in the activation process [189]. 
ILl / ILl RI 
Reactive oxygen intermediates? 
Protein kinase acivation? 
Protease activation? 
Ceramide? 
1 
Plasma memt~r~,n9 
l= r ~  . . . .  ~ Deg raded 
Translocation 
leus 
Fig. 4. Possible routes to NFKB activation. The primary event which 
occurs in NFKB activation is dissociation of the inhibitory component 
I KB, allowing the NFKB complex to translocate to the nucleus. As 
indicated above, several mechanisms have been proposed for this process, 
including generation of reactive oxygen intermediates [192,193], protein 
kinase activation [185,188], proteinase activation [189] and ceramide 
generation [93]. The importance of any of these for ILl action has yet to 
be fully defined. 
Table 2 
ILl-sensitive gene enhancers which contain NFKB and/or AP1 consen- 
sus sequences 
Transcription factor ILl-Regulated target gene Ref. 
NFKB Igr  light chain [161,165] 
IL2 receptor o~ chain [166] 
GM-CSF [167] 
G-CSF [168] 
IL2 [169,170] 
IL6 [171] 
TNFot [172] 
Serum amyloid A [173] 
myc [174] 
E-selectin [175] 
VCAM-1 [176] 
ICAM-1 [177] 
AP1 Collagenase [178] 
Metallothionein [ 179] 
IL2 [158] 
IL8 [180] 
E-selectin [175] 
VCAM-1 [176] 
ICAM-1 [177] 
Proteinase inhibitors have been shown to block the activa- 
tion of NFK B by ILl, indicating that ILl may be activat- 
ing a proteinase important for the process of activation 
[189]. As mentioned previously, the tyrosine kinase in- 
hibitors genistein and herbimycin A have also been shown 
to block activation [138,140], suggesting the involvement 
of a tyrosine kinase. There is also a possibility that the 
MAP kinase pathway is involved, as recent studies involv- 
ing the overexpression of MAP kinase in T cells have 
demonstrated constitutive activation of NFK B and AP1 in 
these cells [190]. This may relate to the likely similarity 
between NFK B activation by ILl and dorsal activation by 
Toll in Drosophila s mentioned above. The importance of 
the raf-l-like kinase pelle for dorsal activation suggests 
that a raf-l-like kinase may be important for the activation 
of NFKB by ILl. raf-1 activates the MAP kinase pathway 
in some cell types [191] and so by analogy this pathway 
may be important for NFK B activation. Furthermore, dom- 
inant negative mutant studies involving raf-1 have also 
shown raf-1 to be critical for NFK B activation in response 
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to a range of stimuli, including TNF [24]. Whether af-1 
becomes activated in response to ILl has yet to be deter- 
mined. As mentioned previously, ceramide may act as a 
second messenger for NFK B activation, although its effect 
may be cell-type specific [94,95]. 
A final model for actiwttion of NFKB has come from 
work with antioxidants which have been shown to inhibit a 
range of stimuli including ILl [192,193]. This suggested 
that reactive oxygen intermediates may be important sec- 
ond messengers for NFK B activation. Hydrogen peroxide 
was also shown to activate NFKB [192]. Recent studies 
which compared the susceptibility of transformed cell lines 
and primary cells to hydrogen peroxide suggest hat the 
ability of reactive oxygen intermediates to activate NFK B 
may be cell-specific and may depend on the intracellular 
oxidative state of individual cell types [194]. Activation of 
NFKB by ILl has been shown to be insensitive to the 
antioxidant N-acetylcysteine in EL4 cells and 1231 N1 
astrocytoma cells [30,195,196]. Another antioxidant, pyrol- 
lidine dithiocarbamate also failed to inhibit NFKB activa- 
tion in 1231 N1 astrocytoma cells [195]. Interestingly, in a 
human endothelial cell line ECV304, the compound again 
failed to inhibit NFKB activation by ILl but was able to 
block activation by TNF and PMA [197]. This further 
questions a role for reactive oxygen intermediates in the 
activation of NFK B by ILl. It is possible that there may be 
several mechanisms by which NFKB can be activated 
which may be dependent on the species of NFKB and 
perhaps more importantly, the species of I KB, as four 
distinct forms have so far been described [198]. 
Pyrollidine dithiocarbarnate and N-acetylcysteine have 
also been used in studies on the induction NFKB-driven 
genes by ILl. Both agents were found to block ILl-in- 
duced IL2 in EL4 Cells [196]. However, in 1231 N1 
astrocytoma cells, where ILl has been shown to induce the 
cell adhesion molecules ICAM-1 and VCAM-1, only 
VCAM-1 proved susceptible [195]. An identical phe- 
nomenon was observed in endothelial cells [199]. These 
results suggest hat the signal leading from the IL1RI to 
changes in gene expression must diverge for these two 
genes. 
6. Conclusions 
Despite intense investig~.tion, a clear signal transduction 
pathway for ILl has yet to emerge. The dramatic activa- 
tion of cells induced by ILl may turn on a number of 
signal transduction pathways which may diverge, adding 
complexity. Furthermore, different pathways may be acti- 
vated in different cell types. Recent evidence of a protein 
kinase cascade involving IvlAP kinases and/or novel pro- 
tein kinases would allow tor the amplification eeded to 
generate a signal from the small number of receptors 
triggered by ILl. These kinases are also likely to activate 
transcription factors such as NFKB, thereby providing a 
link between the receptor and gene expression. Determin- 
ing the nature of these kinases and precisely how they alter 
gene expression represents a major challenge and will 
hopefully lead to the determination of the specific signal 
transduction pathway for ILl. 
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